Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The role of Fas ligand (FasL) in programmed cell death via interaction with its receptor Fas is well characterized. It has been proposed that expression of FasL can confer immune privilege to some organs, allowing them to kill infiltrating lymphocytes and inflammatory cells. However, a number of studies have shown that when tumors or transplants express FasL, rejection often occurs as a consequence of proinflammatory functions of FasL. Here we demonstrate that FasL elicits tumor immunity in a murine melanoma model with weak immunogenicity and low expression of major histocompatibility complex (MHC) class I. We show that protected mice recognize melanocyte differentiation self-antigens. Importantly, tumor immunity is mediated by antibodies, as it can be transferred by serum from protected mice.

Original publication




Journal article


Cancer Cell

Publication Date





315 - 322


Animals, Antibodies, Neoplasm, Autoantigens, Bone Marrow, Cell Differentiation, Cell Division, Cytotoxicity, Immunologic, Dendritic Cells, Disease-Free Survival, Fas Ligand Protein, Flow Cytometry, Green Fluorescent Proteins, Immune Tolerance, Immunoglobulins, Lipopolysaccharides, Luminescent Proteins, Lymphocytes, Tumor-Infiltrating, Melanocytes, Melanoma, Experimental, Membrane Glycoproteins, Mice, Mice, Inbred C57BL, T-Lymphocytes, Transfection, Tumor Cells, Cultured